News | November 15, 2024
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Equity raise to finance growth and investments in the biological space
Subscribe To Our Newsletter & Stay Updated
